Doing an all post-mortem comparative analysis of b
Post# of 30029
Posted On: 09/16/2014 4:50:35 PM
Re: seebisquick #6452
Doing an all post-mortem comparative analysis of brains that show "significant" signs of ALZ, brains that don't show any signs and run LymPro test on those patients too.
I guess it would be very quick for those who have donated their bodies to science for testing.
I think you're on to something but it may be more geared towards TBI/CTE studies.
As for the LP-002 study, just because enrollment was completed 4 days ago, doesn't mean, they weren't enrolling and testing simultaneously. They could have had just 1 or 2 more patients to enroll and test. Which could have been done that afternoon. (Yes, they could have had more)
After all, they are looking to release additional Univariate Data (80% Floor) Not the Multi-Varirate which GC said the can get 90-95%.
http://ir.amarantus.com/company-news/detail/1...mpro-testr
I guess it would be very quick for those who have donated their bodies to science for testing.
I think you're on to something but it may be more geared towards TBI/CTE studies.
As for the LP-002 study, just because enrollment was completed 4 days ago, doesn't mean, they weren't enrolling and testing simultaneously. They could have had just 1 or 2 more patients to enroll and test. Which could have been done that afternoon. (Yes, they could have had more)
After all, they are looking to release additional Univariate Data (80% Floor) Not the Multi-Varirate which GC said the can get 90-95%.
http://ir.amarantus.com/company-news/detail/1...mpro-testr
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼